Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Risk Benefit Ratio of Glucocorticoids in SLE: Have Things Changed over the Past 40 years?
George Stojan, Michelle Petri
Current Treatment Options in Rheumatology (2017) Vol. 3, Iss. 3, pp. 164-172
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Novel paradigms in systemic lupus erythematosus
Thomas Dörner, Richard Furie
The Lancet (2019) Vol. 393, Iss. 10188, pp. 2344-2358
Closed Access | Times Cited: 471
Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases
Seong A. Shin, Byeong Jun Joo, Jun Seob Lee, et al.
Molecules (2020) Vol. 25, Iss. 24, pp. 5932-5932
Open Access | Times Cited: 111
Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus
Mengchen Guo, Huixia Wang, Sixie Xu, et al.
Gut Microbes (2020) Vol. 11, Iss. 6, pp. 1758-1773
Open Access | Times Cited: 97
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
Ruth Fernandez‐Ruiz, Jacqueline L Paredes, Timothy B. Niewold
Translational research (2020) Vol. 232, pp. 13-36
Open Access | Times Cited: 89
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Celline Cardoso Almeida-Brasil, John G. Hanly, Murray B. Urowitz, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 370-378
Open Access | Times Cited: 75
The role of complement in kidney disease
Vojtěch Petr, Joshua M. Thurman
Nature Reviews Nephrology (2023) Vol. 19, Iss. 12, pp. 771-787
Closed Access | Times Cited: 39
Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality—a national cohort study
Martina Frodlund, Andreas Jönsen, Lauren Remkus, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 4, pp. 1104-1112
Open Access | Times Cited: 17
A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors
Chaoyu Gu, Rui Zhao, Xiaomei Zhang, et al.
Archives of Osteoporosis (2019) Vol. 15, Iss. 1
Closed Access | Times Cited: 52
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials
Eric F. Morand, Ronald van Vollenhoven, Richard Furie, et al.
Annals of the Rheumatic Diseases (2025)
Closed Access
Lupus ABC spearheading a new era of collaboration to advance lupus drug development
Hoang Nguyen, Teodora Staeva
Nature Reviews Rheumatology (2025)
Closed Access
Glucocorticoid in systemic lupus erythematosus: the art beyond science
Tsz Ching Mok, Chi Chiu Mok
Expert Review of Clinical Immunology (2025)
Closed Access
Greetings from the editor 2024
Josef S Smolen
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 1, pp. 1-3
Open Access | Times Cited: 3
Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome
Fernanda-Isadora Corona-Meraz, Mónica Vázquez-Del Mercado, Flavio Sandoval-García, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1988-1988
Open Access | Times Cited: 3
The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations
Evandro Mendes Klumb, Morton Scheinberg, Viviane Angelina de Souza, et al.
Lupus (2021) Vol. 30, Iss. 10, pp. 1684-1695
Open Access | Times Cited: 19
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety
Angélica María Téllez-Arévalo, Abraham Quaye, Luis Carlos Rojas-Rodríguez, et al.
Medicina (2022) Vol. 59, Iss. 1, pp. 56-56
Open Access | Times Cited: 13
Glucocorticoids in rheumatology: myths vs. reality
Д. Г. Рекалов, I.Yu. Golovach, И. А. Бринер, et al.
MOJ Orthopedics & Rheumatology (2024) Vol. 16, Iss. 1, pp. 17-23
Open Access | Times Cited: 2
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment
Íñigo Rúa-Figueroa Fernández de Larrinoa, María José Cuadrado Lozano, Carlos Marras, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 7, pp. 821-829
Open Access | Times Cited: 11
Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard‐of‐Care Management of Systemic Lupus Erythematosus in Canada
Zahi Touma, Sheena Kayaniyil, Anna Parackal, et al.
ACR Open Rheumatology (2024) Vol. 6, Iss. 9, pp. 531-539
Open Access | Times Cited: 1
Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications
Liuting Zeng, Yan Li, Xiang Wang, et al.
Journal of Autoimmunity (2024) Vol. 150, pp. 103350-103350
Closed Access | Times Cited: 1
Glomerular Disease and Pregnancy
Sarah Gleeson, Liz Lightstone
Advances in Chronic Kidney Disease (2020) Vol. 27, Iss. 6, pp. 469-476
Closed Access | Times Cited: 10
Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice
Xin Wei, Gang Zhao, Xiaobei Wang, et al.
Nanomedicine Nanotechnology Biology and Medicine (2020) Vol. 29, pp. 102266-102266
Open Access | Times Cited: 9
Primary nephrotic syndrome relapse within 1 year after glucocorticoid therapy in children is associated with gut microbiota composition at syndrome onset
Helen C. Wang, Wei Qu, Qiurong Chen, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 9, pp. 1969-1980
Closed Access | Times Cited: 6
Systemic Lupus Erythematosus
Bhavyata Parag, W. Towers
The American Pharmacists Association eBooks (2017)
Closed Access | Times Cited: 7
Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity
Neha N. Parayath, Shuai Hao, Sirkka B. Stephan, et al.
Journal of Controlled Release (2021) Vol. 339, pp. 553-561
Open Access | Times Cited: 7
Predictors of Infection in Children with Systemic Lupus Erythematosus: A Single Center Study in Indonesia
Maria Kristianti Sari, Cahya Dewi Satria, Eggi Arguni
Global Pediatric Health (2021) Vol. 8
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top